13F Holdings
中文EN

LENZ LENZ Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%

Returns

ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$19.09M$0———
Cost of revenue$418,000$0———
Gross profit$18.67M$0———
R&D expense$18.67M$29.80M$59.50M$72.79M$37.93M
SG&A expense$91.14M$28.81M$12.93M$32.85M$22.51M
Operating income-$91.14M-$58.61M-$72.43M-$105.64M-$60.44M
Pretax income-$81.62M-$49.77M-$70.15M——
Income tax$502,000$1,000-$179,000$0$0
Net income-$82.13M-$49.77M-$69.97M-$101.05M-$70.76M
EBITDA-$90.85M-$58.55M-$72.41M-$103.29M-$59.71M
EPS (basic)-2.85-2.34-35.71-1.84-2.45
EPS (diluted)-2.85-2.34-35.71-1.84-2.45
Weighted avg. shares (diluted)28.81M21.28M1.96M54.87M28.92M
Balance sheet
Cash & equivalents$25.18M$20.16M$35.14M$44.44M$376.98M
Short-term investments——$30.65M$220.50M$0
Receivables$329,000$0———
Inventory$2.94M$0———
Current assets$301.41M$211.92M$67.24M$275.37M$381.74M
PP&E, net$1.19M$651,000$54,000$22.63M$6.51M
Total assets$305.88M$215.30M$70.38M$321.90M$401.99M
Current liabilities$21.19M$10.41M$18.51M$13.04M$12.14M
Total liabilities$21.54M$11.22M$19.70M$25.61M$17.94M
Shareholders' equity$284.34M$204.08M-$92.71M-$24.17M$384.05M
Shares outstanding31.34M27.52M1.97M58.22M58.01M
Cash flow statement
Operating cash flow-$69.17M-$59.39M-$60.38M-$87.98M-$52.85M
Capital expenditure$827,000$468,000$30,000$6.59M$5.74M
Free cash flow-$70.00M-$59.86M-$60.41M-$94.57M-$58.59M
Investing cash flow-$75.67M-$154.48M-$29.62M-$241.86M-$5.74M
Financing cash flow$149.75M$199.00M$80.70M$597,000$417.47M
Depreciation & amortization$287,000$58,000$15,000$2.35M$734,000
Stock-based compensation$12.55M$6.37M$1.34M$13.53M$7.87M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.